webinar register page

Methamphetamines, MSMs, and HIV
This session is part of NAHEWD's national webinar series Bridging HIV and SUD: Innovations in the Field. The series will highlight various innovative models and approaches to treating substance use disorder (SUD) in people at risk for and living with HIV.

This presentation will address the use of methamphetamine by the MSM community, its relation to HIV/AIDS, and treatment approaches. By the end of this session, participants can expect to:

1. Increase their knowledge about crystal methamphetamine.
2. Understand how and why it is used in the MSM community.
3. Learn about treatment options for those wanting to change their use.

Jul 1, 2022 12:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information


Martin C. McElhiney, PhD
Assistant Professor of Clinical Medical Psychology in Psychiatry @College of Physicians and Surgeons, Columbia University
Martin McElhiney is an Assistant Professor of Clinical Medical Psychology in Psychiatry at Columbia University, and Research Scientist at New York State Psychiatric Institute. Most of his career has been spent understanding the intersection of medical illnesses such as HIV/AIDS and the diagnosis and treatment of psychiatric conditions including depression and substance use. Early work included conducting randomized clinical trials of novel antidepressants such as testosterone and DHEA in people with HIV/AIDS. He was the principal investigator of a combined modafinil/motivational enhancement therapy for HIV+ MSM methamphetamine users and a co-investigator on a NIDA study: Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder. He is currently working as a therapist on three studies investigating the use of ketamine to enhance mindfulness-based therapies for the treatment of substance use disorders.